Meprobamate

Mechanism :

Affects the thalamus and limbic system; also appears to inhibit multineuronal spinal reflexes.

Indication :

Management of anxiety disorders

Contraindications :

Hypersensitivity to meprobamate, related compounds, or any component of the formulation; acute intermittent porphyria.

Dosing :

Oral:

Children ≥6 years:

200 to 600 mg/day in 2 to 3 divided doses.

Adolescents:

1,200 to 1,600 mg/day in 3 to 4 divided doses; Maximum: 2,400 mg/day.

Adverse Effect :

Abnormal electroencephalogram, cardiac arrhythmia, peripheral edema, palpitations, severe hypotension, Ataxia, chills, dizziness, drowsiness, euphoria, headache, dermatitis, erythema multiforme, skin rash, Stevens-Johnson syndrome, Exacerbation of porphyria, Diarrhea, nausea, proctitis, Agranulocytosis, aplastic anemia, bruise, eosinophilia, immune thrombocytopenia, Anaphylaxis, angioedema, hypersensitivity reaction, weakness, fever, bronchospasm.

Interaction :

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.
Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.

Hepatic Dose :

Reduction of the dose may be needed.